EUVIMEDEUVIMED entdecken
Crossref

Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung

Michael A. Nauck, Horst Harald Klein

Diabetologie und Stoffwechsel · 01.06.2026 · 21 (03) · 179-189

DOI: 10.1055/a-2607-5520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.06.2026. Verfasst von Michael A. Nauck und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With GLP-1 RA therapy, residual gastric content (including solid components) will be found more frequently at the time of planned endoscopy or general anaesthesia/surgery than without GLP-1 RA therapy. It remains unclear, whether this is mainly due to a diagnosis of diabetes mellitus (e.g., with autonomic neuropathy of the gastrointestinal tract), or to GLP-1 RA therapy itself. A lasting deceleration of gastric emptying is typical for short-acting compounds/preparations, with long-acting RA this effect is subject to “tachyphylaxis” (reduction of this effect) over time. Despite clearly elevated risks for retained gastric contents with GLP-1 RA therapy, the rate of patients experiencing pulmonary aspiration after the procedures is comparable with and without GLP-1 RA therapy (difference not significant). Leaving out injections of short-acting GLP-1 RA injections for 24 h (including the morning of a planned procedure) will avoid residual effects on the velocity of gastric emptying with certainty. Long-acting GLP-1 RA would have to be paused for too long a period, if residual effects on gastric emptying were to be ruled out. The therapeutic safety can most likely be improved by ultrasound examinations before endoscopic procedures or the induction of general anaesthesia (residual gastric content?), prompting further intake of clear liquid nutrients only until the delayed procedure.

Zitieren

APA

Nauck, M. A., & Klein, H. H. (2026). Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung. Diabetologie und Stoffwechsel, 21(03), 179-189. https://doi.org/10.1055/a-2607-5520

Vancouver

Nauck MA, Klein HH. Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung. Diabetologie und Stoffwechsel. 2026;21(03):179-189. doi:10.1055/a-2607-5520

BibTeX
@article{Nauck2026,
  author = {Nauck, Michael A. and Klein, Horst Harald},
  title = {Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung},
  journal = {Diabetologie und Stoffwechsel},
  year = {2026},
  volume = {21},
  number = {03},
  pages = {179--189},
  doi = {10.1055/a-2607-5520}
}
Kostenlos starten →